The senolytic landscape

FOXO4-DRI among its rivals

FOXO4-DRI is one entry in a crowded field of senolytics. Others, dasatinib plus quercetin, fisetin, navitoclax, reached human pilots years ago, and one high-profile candidate failed a Phase 2 trial. Placing FOXO4-DRI beside them shows both what is distinctive about it and how far behind it sits on the road to the clinic.

This unit maps the class, walks through the human pilot data other senolytics have that FOXO4-DRI lacks, and studies two cautionary failures the field learned from.